SEC Company Response from AGENUS INC (AGEN) (CIK 0001098972) (AGEN) — Jun 23, 2008
AGENUS INC (AGEN) (CIK 0001098972)
Date: June 23, 2008 · CIK: 0001098972 · Accession: 0001193125-08-138083
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-151244
Letter
VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Re: Registration Statement on Form S-3 filed by Antigenics Inc. with the Securities and Exchange Commission (the “Commission”) on May 29, 2008 (File No. 333-151244) (the “Registration Statement”)
Dear Mr. Pitko,
In connection with the above-referenced filing, Antigenics Inc. (the “Company”) hereby acknowledges that (i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement, (ii) the action of the Commission or the staff pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement, and (iii) the Company may not assert the declaration of effectiveness as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company requests effectiveness of the above referenced Registration Statement at 4:45 PM EST on June 25, 2008, or as soon thereafter as practicable.
Please call the undersigned at (212) 994-8200 as soon as the above-referenced filing has become effective.
Very truly yours,
ANTIGENICS INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request Antigenics Inc. 162 Fifth Avenue, Suite 900 New York, New York 10010 June 23, 2008 VIA EDGAR Mr. Bryan Pitko Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Re: Registration Statement on Form S-3 filed by Antigenics Inc. with the Securities and Exchange Commission (the “Commission”) on May 29, 2008 (File No. 333-151244) (the “Registration Statement”) Dear Mr. Pitko, In connection with the above-referenced filing, Antigenics Inc. (the “Company”) hereby acknowledges that (i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement, (ii) the action of the Commission or the staff pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement, and (iii) the Company may not assert the declaration of effectiveness as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company requests effectiveness of the above referenced Registration Statement at 4:45 PM EST on June 25, 2008, or as soon thereafter as practicable. Please call the undersigned at (212) 994-8200 as soon as the above-referenced filing has become effective. Very truly yours, ANTIGENICS INC. By: /s/ Garo H. Armen Name: Garo H. Armen Title: Chief Financial Officer